ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation is a biotechnology company focused on developing and commercializing products that support the health and productivity of livestock. Based in Portland, Maine, the company uses antibody-based technologies to create veterinary products designed to help prevent and treat common diseases in food-producing animals.

ImmuCell’s principal product is First Defense, an oral antibody treatment for newborn calves. The product is intended to provide immediate, passive protection against pathogens associated with bovine neonatal diarrhea, including strains of Escherichia coli, coronavirus and rotavirus. First Defense products are marketed through veterinary and livestock distribution channels, primarily serving cattle producers in North America.

Founded in 1987, ImmuCell has also pursued additional livestock-health products, including therapies for bovine mastitis. The company’s operations remain centered on research, product development, regulatory approval and manufacturing of biological products for the animal-health market. Michael Brigham has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $9.69 to $10.11
• 50-Day Range: $9.58 to $11.24
• 52-Week Range: $4.52 to $12.10
• Volume: 4,451 shs
• Average Volume: 13,895 shs
• Market Capitalization: $89.71 million
• P/E Ratio: 123.52
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ImmuCell Stock Analysis - MarketRank™

ImmuCell scored higher than 19% of companies evaluated by MarketBeat, and ranked 826th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

ImmuCell has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

ImmuCell has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmuCell is 123.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 42.18.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmuCell is 123.52, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 214.73.

Price to Book Value per Share Ratio

ImmuCell has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 1.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently increased by 2.90%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmuCell does not currently pay a dividend.

Dividend Growth

ImmuCell does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

ImmuCell has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ImmuCell this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmuCell insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of ImmuCell is held by insiders.

Percentage Held by Institutions

13.47% of the stock of ImmuCell is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 73
• Year Founded: 1982

Profitability

• EPS (Trailing Twelve Months): $0.08
• Trailing P/E Ratio: 123.52
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.04 million
• Net Margins: 2.57%
• Pretax Margin: 2.78%
• Return on Equity: 2.69%
• Return on Assets: 1.76%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 4.75
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: $27.64 million
• Price / Sales: 3.25
• Cash Flow: $0.19 per share
• Price / Cash Flow: 51.48
• Book Value: $2.99 per share
• Price / Book: 3.30

Miscellaneous

• Outstanding Shares: 9,080,000
• Free Float: 8,564,000
• Market Cap: $89.71 million
• Optionable: Not Optionable
• Beta: 0.54